Shopping Cart
Remove All
Your shopping cart is currently empty
Zuberitamab
Copy Product Info
😃Good
Catalog No. T76946Cas No. 2251143-19-6
Alias HS006
Zuberitamab (HS-20090) is a humanized IgG1 monoclonal antibody targeting CD20. The compound specifically binds to CD20 on the surface of B cells, facilitating the depletion of malignant B cells through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and the direct induction of apoptosis. In experimental studies, Zuberitamab serves as a potent tool for B-cell depletion to investigate hematological malignancies such as Non-Hodgkin Lymphoma (NHL).
Zuberitamab
Zuberitamab
Copy Product Info😃Good
Catalog No. T76946Alias HS006Cas No. 2251143-19-6
Zuberitamab (HS-20090) is a humanized IgG1 monoclonal antibody targeting CD20. The compound specifically binds to CD20 on the surface of B cells, facilitating the depletion of malignant B cells through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and the direct induction of apoptosis. In experimental studies, Zuberitamab serves as a potent tool for B-cell depletion to investigate hematological malignancies such as Non-Hodgkin Lymphoma (NHL).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Zuberitamab (HS-20090) is a humanized IgG1 monoclonal antibody targeting CD20. The compound specifically binds to CD20 on the surface of B cells, facilitating the depletion of malignant B cells through antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and the direct induction of apoptosis. In experimental studies, Zuberitamab serves as a potent tool for B-cell depletion to investigate hematological malignancies such as Non-Hodgkin Lymphoma (NHL). |
| Synonyms | HS006 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID | |
| Target | CD20 |
| Cas No. | 2251143-19-6 |
| Isotype | IgG1 |
| Storage | store at low temperature | store at -20°C | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Zuberitamab | purchase Zuberitamab | Zuberitamab cost | order Zuberitamab
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.